Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
423.64
-3.59 (-0.84%)
Mar 25, 2025, 4:00 PM EST - Market closed
Elevance Health Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Elevance Health stock have an average target of 530.83, with a low estimate of 405.4 and a high estimate of 649. The average target predicts an increase of 25.30% from the current stock price of 423.64.
Analyst Consensus: Buy
* Price targets were last updated on Jan 29, 2025.
Analyst Ratings
The average analyst rating for Elevance Health stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Buy | 8 | 9 | 9 | 9 | 9 | 9 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Argus Research | Argus Research | Hold Reiterates $405 | Hold | Reiterates | $405 | -4.31% | Jan 29, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $483 → $478 | Buy | Maintains | $483 → $478 | +12.83% | Jan 28, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $485 | Buy | Reiterates | $485 | +14.48% | Jan 24, 2025 |
| Barclays | Barclays | Buy Maintains $501 → $512 | Buy | Maintains | $501 → $512 | +20.86% | Jan 24, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $520 → $480 | Strong Buy | Maintains | $520 → $480 | +13.30% | Jan 6, 2025 |
Financial Forecast
Revenue This Year
194.69B
from 176.81B
Increased by 10.11%
Revenue Next Year
208.84B
from 194.69B
Increased by 7.27%
EPS This Year
34.49
from 25.68
Increased by 34.31%
EPS Next Year
39.44
from 34.49
Increased by 14.36%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 213.9B | 231.4B | 252.3B | |
| Avg | 194.7B | 208.8B | 228.7B | |
| Low | 179.1B | 192.2B | 211.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 21.0% | 18.9% | 20.8% | |
| Avg | 10.1% | 7.3% | 9.5% | |
| Low | 1.3% | -1.3% | 1.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 36.54 | 43.68 | 50.66 | ||
| Avg | 34.49 | 39.44 | 46.37 | ||
| Low | 30.32 | 34.59 | 42.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 42.3% | 26.6% | 28.4% | ||
| Avg | 34.3% | 14.4% | 17.6% | ||
| Low | 18.1% | 0.3% | 7.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.